Issue 2, 2012

Development of second generation epigenetic agents

Abstract

DNA in the nucleus of eukaryote cells is packaged in the nucleosomes around histone proteins, and this is highly organized and tightly regulated to control gene transcription. This packaging is not static and the histone tails undergo a wide variety of post-translational modifications that regulate gene transcription, and these patterns have been shown to be aberrantly regulated in multiple disease states. The biology behind these histone modifications is being elucidated, and it is now known that multiple proteins control the writing, reading and removal of these covalent histone modifications. The first agents, vorinostat and romidepsin, which inhibit histone deacetylase enzymes responsible for removing one of these marks have been approved for use in humans. This review focuses on the progress in the development of the second generation of epigenetic modifiers able to modulate histone marks, and restore normal gene transcription.

Graphical abstract: Development of second generation epigenetic agents

Article information

Article type
Review Article
Submitted
01 Aug 2011
Accepted
17 Sep 2011
First published
26 Oct 2011

Med. Chem. Commun., 2012,3, 135-161

Development of second generation epigenetic agents

P. Jones, Med. Chem. Commun., 2012, 3, 135 DOI: 10.1039/C1MD00199J

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Spotlight

Advertisements